Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ARTV, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Umbilical Cord Blood-derived CD16-expressing… | Non Hodgkin Lymphoma | Phase 1/2 · NCT04673617 | Completed |
| Allogeneic Anti-HER2 CAR-NK Cells AB-201 | Breast Cancer | Phase 1/2 · NCT05678205 | Withdrawn |
| Acimtamig (AFM13) | Relapsed or Refractory Hodgkin Lymphoma | Phase 2 · NCT05883449 | Terminated |
| Allogeneic NK Cells | Refractory Rheumatoid Arthritis (RA) | Phase 2 · NCT06991114 | Recruiting |
| Bendamustine | Non Hodgkin Lymphoma | Phase 1/2 · NCT04673617 | Completed |
| Fludarabine | Non Hodgkin Lymphoma | Phase 1/2 · NCT04673617 | Completed |
| GCC2005 | Lymphoma, T-Cell | Phase 1 · NCT06699771 | Recruiting |
Also used in these trials (approved or third-party drugs, not ARTV's own candidates): Cyclophosphamide, Interleukin-2, Rituximab, Obinutuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ARTV holds $319.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.4M/quarter from operations, an estimated runway of 39.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARTV files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| GC Corp. 10% owner |
Insider | 5,999,703 | 12.14% | 2026-05-11 |
| VIKING GLOBAL INVESTORS LP | Institution (13G, 5%+) | 2,604,166 | 5.27% | 2026-05-11 |
| Blackstone Inc | Institution (13F) | 2,403,437 | 4.86% | 2026-06-30 |
| 5AM Venture Management, LLC | Institution (13F) | 2,353,304 | 4.76% | 2026-06-30 |
| Venrock Adviser, LLC | Institution (13F) | 2,043,596 | 4.13% | 2026-06-30 |
| Franklin Resources, Inc. | Institution (13F) | 1,997,223 | 4.04% | 2026-06-30 |
| Caligan Partners, LP | Institution (13F) | 1,736,111 | 3.51% | 2026-06-30 |
| Fred Aslan Chief Executive Officer, Director · +470,000 options |
Insider | 1,457,428 | 2.95% | 2026-11-02 |
| Vanguard Capital Management LLC | Institution (13F) | 981,815 | 1.99% | 2026-06-30 |
| Samsara BioCapital, LLC | Institution (13F) | 954,861 | 1.93% | 2026-06-30 |
| Blue Owl Capital Holdings LP | Institution (13F) | 874,542 | 1.77% | 2026-06-30 |
| Propel Bio Management, LLC | Institution (13F) | 696,436 | 1.41% | 2026-06-30 |
Share count 49,432,351 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-15 filed 2026-09-15 |
Aslan Fred |
Award (A) | 110,000 | – | 1,604,765 |
| 2026-09-15 filed 2026-09-15 |
Aslan Fred |
Option award (A) | 315,000 | – | – |
| 2026-09-10 filed 2026-09-14 |
Aslan Fred |
Option award (A) | 155,000 | – | – |
| 2026-09-10 filed 2026-09-14 |
Aslan Fred |
Award (A) | 45,000 | – | 1,494,765 |
| 2026-09-10 filed 2026-09-14 |
Stoppel Laura |
Option award (A) | 16,250 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARTV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →